Abstracts tagged "corticosteroids"

Abstract Number: 0990 • ACR Convergence 2023
Association of Treatment and Disease Activity with Antibiotic Use and Hospitalized Infection Among People Living with Rheumatoid Arthritis: Baseline Data from a Longitudinal Study in the ArthritisPower Registry
Kelly Gavigan¹, Esteban Rivera², Odette Kolenky³, Cassie Clinton⁴, Emily Holladay⁴, David Curtis⁵, Laura Stradford⁶, Jeffrey Curtis⁴, W. Benjamin Nowell⁶, Christian Curtis⁷ and Michael George⁸, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Global Healthy Living Foundation, Long Island City, NY, ³Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Global Healthy Living Foundation, San Francisco, CA, ⁶Global Healthy Living Foundation, Nyack, NY, ⁷Illumination Health, Birmingham, AL, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: Infections are a major contributor to morbidity and mortality in patients (pts) with rheumatoid arthritis (RA). Little is known about the risk of non-serious…
Abstract Number: 1133 • ACR Convergence 2023
Exploring the Clinical Characteristics and Correlation with Corticosteroid Dependence in Polymyalgia Rheumatica (PMR) Patients: Insights from an Academic Center
William Rigby¹, Todd Mackenzie², Emily Campbell¹, Joshua Skydel³, Bryan Savage¹, Monica Dimambro² and Vivekanand Tiwari¹, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Dartmouth College, Hanover, NH, ³Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Polymyalgia rheumatica (PMR) treatment is primarily based on long-term corticosteroids, which results in significant toxicities. Studies1,2 have shown that patients with PMR are exposed…
Abstract Number: 1327 • ACR Convergence 2023
Effects of Long-Term Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis on Body Weight and Blood Pressure: A Pooled Analysis of Individual Patient Data from Five Randomised Trials
Andriko Palmowski¹, Sabrina Mai Nielsen², Zhivana Boyadzhieva³, Linda Hartman⁴, Judith Oldenkott⁵, Björn Svensson⁶, Ingiäld Hafström⁷, Siegfried Wassenberg⁸, Ernest Choy⁹, John Kirwan¹⁰, Robin Christensen¹¹, Maarten Boers¹² and Frank Buttgereit¹³, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ³Charité Universitatsmedizine - Berlin, Berlin, Germany, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁵Charite - University Medicine Berlin, Berlin, Germany, ⁶Lund University, Lund, Sweden, ⁷Karolinska Institutet, Stockholm, Sweden, ⁸Rheumazentrum Ratingen, Ratingen, Germany, ⁹Section of Rheumatology, Cardiff University, Cardiff, United Kingdom, ¹⁰University of Bristol, Bristol, United Kingdom, ¹¹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ¹²Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ¹³Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany
Background/Purpose: High-dose glucocorticoids (GCs) can cause weight gain and hypertension. It is unclear whether GCs at ≤7.5mg/day prednisone equivalent ("low dose"), administered for rheumatoid arthritis…
Abstract Number: 1446 • ACR Convergence 2023
Glucocorticoids Use Is a Major Driver of Self-perceived Depression in Systemic Lupus Erythematosus: Insights from a Large, Prospective and Multicenter Study Using RELESSERPROS Register’s Database
Iñigo Rúa-Figueroa¹, JULIA MARTINEZ BARRIO², Norman Jiménez³, Maria Galindo-Izquierdo⁴, Esther Uriarte Isacelaya⁵, Antonio Fernandez-Nebro⁶, Jaime Calvo- Alén⁷, SARA MANRIQUE⁸, Jose Rosas⁹, Rocío Caño-Alameda¹⁰, Javier Narvaez¹¹, Inmaculada Ros¹², Elena Aurrecoechea Aguinaga¹³, Vicente Torrente-Segarra¹⁴, Clara Sanguesa Gomez¹⁵, Mercedes Freire González¹⁶, Eva Tomero Muriel¹⁷, Loreto Horcada¹⁸, Clara Moriano Morales¹⁹, Mireia Moreno²⁰, Carlota Iñíguez²¹, Ricardo Blanco²², Ana Pérez Gómez²³, Jose Luis Andreu-Sánchez²⁴, Sandra Garrote Corral²⁵, Santiago Muñoz²⁶, Gema Bonilla²⁷, Nuria Lozano Rivas²⁸, Carlos Montilla-Morales²⁹, Oihane Ibarguengoitia-Barrena³⁰, Lorena Expósito³¹, Elia Valls-Pascual³², Angela Pecondon-Español³³, Sergio Machin³⁴, Eva Salgado-Pérez³⁵, Celia Erausquin³⁶, TAREK CARLOS SALMAN MONTE³⁷, Raúl Menor-Almagro³⁸, Alejandro Muñoz³⁹, Irene Altabas Gonzalez⁴⁰, Jorge Juan Fragio⁴¹ and Jose-Maria Pego-Reigosa⁴², ¹Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ³IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, ⁴Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, ⁵Rheumatology, University Hospital of Donosti, San Sebastián, Spain, ⁶Hospital Regional Universitario de Málaga, Malaga, Spain, ⁷Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ⁸Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁹Hospital Marina Baixa, Alicante, Spain, ¹⁰Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, ¹¹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹²Rheumatology Department HUSLL, Palma de Mallorca, Spain, ¹³Department of Rheumatology, Hospital Sierrallana, Torrelavega, Spain, ¹⁴Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, ¹⁵Severo Ochoa Hospital, Madrid, Spain, ¹⁶Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁷Rheumatology, Hospital La Princesa, Madrid, Spain, ¹⁸Hospital de Navarra, Pamplona, Spain, ¹⁹Rheumatology, Hospital Universitario de León, León, Spain, ²⁰Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ²¹Hospital Lucus Augusti, Lugo, Spain, ²²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²³Rheumatology, Hospital Principe de Asturias, Alcalá de Henares, Spain, ²⁴Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ²⁵Hospital Ramón y Cajal, Madrid, Spain, ²⁶Hospital Infanta Sofia, Madrid, Spain, ²⁷Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁸Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²⁹Rheumatology, University Hospital of Salamanca, Salamanca, Spain, ³⁰Galdakao-Usansolo University Hospital, Bilbao, Spain, ³¹Rheumatology Unit, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain, ³²Hospital Universitario Doctor Peset. Alicante, Spain., Valencia, Spain, ³³Hospital Miguel Servet, Zaragoza, Spain, ³⁴CHUIMI, Las Palmas de Gran Canaria, Spain, ³⁵Department of Rheumatology, University Hospital of Ourense, Ourense, Spain, ³⁶Rheumatology Department Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ³⁷Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ³⁸Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ³⁹Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, ⁴⁰Complejo Hospitalario Universitario de Vigo, IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, ⁴¹Hospital General Universitario Valencia, Valencia, Spain, ⁴²Rheumatology, Hospital do Meixoeiro, Vigo, Spain
Background/Purpose: The prevalence of depression and associated factors in systemic lupus erythematosus (SLE) are not well known and there are no longitudinal studies addressing this…
Abstract Number: 1523 • ACR Convergence 2023
The Risk of Scleroderma Renal Crisis from Intraarticular Corticosteroid Injection in Systemic Sclerosis
Muruganandam Maheswari, Eyerusalem Akpan, Matthew Mcelwee, Meredith Keller, Angie Ariza - Hutchinson, Rosemina Patel, Wilmer Sibbitt, Frank O'Sullivan, Sharon nunez, N. Suzanne Emil and Roderick Fields, University of New Mexico, Albuquerque, NM
Background/Purpose: Scleroderma renal crisis (SRC) is a rare but a life-threatening complication of systemic sclerosis (SSc), affecting 2-15% of patients with SSc. SRC has been…
Abstract Number: 024 • 2023 Pediatric Rheumatology Symposium
Effects of Corticosteroids on Central Nervous System Microvascular Properties Assessed by Neuroimaging
Mark DiFrancesco, Ekemini Ogbu, Catherine Robben, Jennifer Huggins and Hermine Brunner, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Prior research suggests that microvascular (MV) changes might be a biomarker for central nervous system (CNS) involvement of patients with systemic lupus erythematosus (SLE).…
Abstract Number: 028 • 2023 Pediatric Rheumatology Symposium
Achieving Medication-Free Remission in Juvenile Dermatomyositis
Harneet Ghumman¹, Ilaria Maccora², Hermine Brunner¹, Amy Cassedy³, Mekibib Altaye², Asra Firdous¹, Alexei Grom¹, Daniel Lovell¹, Angela Merritt¹, Megan Quinlan-Waters¹ and Sheila Angeles-Han², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by symmetric proximal muscle weakness, distinct rash, and a risk for calcinosis. Systemic immunosuppression is needed. Evidence is limited…
Abstract Number: L17 • ACR Convergence 2022
Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis
Robert Maughan¹, Andrew Porter¹, Chanaka Dahanayake², Claudia Ianonne¹, Ritu Alapat¹, Charis Pericleous¹, Taryn Youngstein³ and Justin Mason¹, ¹Imperial College London, London, United Kingdom, ²Barts Health NHS Trust, London, United Kingdom, ³Imperial NHS Trust, London, United Kingdom
Background/Purpose: Immunosuppression in Takayasu Arteritis (TA) reduces the risk of arterial damage and disease progression. However, long-term use of glucocorticoids (GC) and other immunosuppressants carries…
Abstract Number: 0134 • ACR Convergence 2022
Combination Treatment with Baricitinib and Pulse Steroids in Severe COVID19: A
Francesco Ferro¹, Elena Elefante², Italiano Nazzareno², Gaetano La Rocca³, Davide Schilirò², Michele Moretti², Roberto Mozzo⁴, De Simone Luigi⁴, Chiara Baldini⁵ and Marta Mosca², ¹Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ²University of Pisa, Pisa, Italy, ³University of Pisa, Rheumatology Unit, Palermo, Palermo, Italy, ⁴Anesthesiology & Intensive Care Unit/Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁵University of Pisa, Pisa, Pisa, Italy
Background/Purpose: Growing evidence from RCTs and real-life experiences has highlighted important similarities between severe COVID19 and rapidly progressive interstitial lung diseases (RP-ILD) occurring in connective…
Abstract Number: 2004 • ACR Convergence 2022
Which Route and Dose of Corticosteroids Is Most Effective in Inducing Remission in Early Rheumatoid Arthritis? A Systematic Literature Review and Meta-analysis
Laura Parker¹ and Nicola Gullick², ¹University of Warwick, Coventry, United Kingdom, ²University Hospital Coventry & Warwickshire; Warwick Medical School, University of Warwick, Coventry, United Kingdom
Background/Purpose: Current NICE guidance for rheumatoid arthritis (RA) states that glucocorticoids may be used for bridging therapy and to rapidly decrease inflammation in acute flares1.…
Abstract Number: 0353 • ACR Convergence 2022
Steroid-Induced Diabetes in Lupus Nephritis Patients: Classic Risk Factors or a Different Type of Diabetes?
Cristian Alejandro Dimas Ramírez¹, André Fortanell-Meza¹, Diego San Agustin-Morales¹, Eduardo Brenner Muslera², Juan Mejia-Vilet³, Paloma Almeda-Valdes⁴, Paola Vázquez Cárdenas⁵, F. Javier Merayo-Chalico⁶ and Ana Barrera-Vargas¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ²School of Medicine of Universidad Panamericana, Ciudad de México, Mexico, ³National Autonomous University of Mexico, Ciudad de México, Mexico, ⁴Department of Endocrinology and Metabolism, and the Research Unit of Metabolic Diseases. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ⁵Hospital General Dr. Manuel Gea González, Ciudad de México, Mexico, ⁶Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirn", Ciudad de México, Mexico
Background/Purpose: Glucocorticoids are frequently employed in the treatment of systemic lupus erythematosus (SLE) patients and play a critical role in the induction therapy of lupus…
Abstract Number: 2005 • ACR Convergence 2022
Comparison of Treatment and Disease Activity in the Early Stage of Onset in Patients with Elderly-onset vs Younger-onset Rheumatoid Arthritis Using Data of National Database of Rheumatic Diseases in Japan (NinJa)
Toshihiro Matsui¹ and Shigeto Tohma², ¹NHO Sagamihara National Hospital, Kanagawa, Japan, ²National Hospital Organization Tokyo National Hospital, Dallas, TX
Background/Purpose: To clarify the current status and issues concerning treatment in the early stage of onset in patients with elderly-onset rheumatoid arthritis (RA) in Japan.Methods:…
Abstract Number: 0354 • ACR Convergence 2022
Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients by Cumulative Corticosteroid Dose over 1 Year: Real-World Observation of Commercially Insured Adults in the United States
Sandra Sze-jung Wu¹, Allison Perry², Helen Varker³, Rich Bizier³, Liisa Palmer³ and Gary Bryant⁴, ¹AstraZeneca, Hockessin, DE, ²IBM Watson Health, New York, NY, ³Merative, Cambridge, MA, ⁴AstraZeneca, New Castle, DE
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, heterogeneous disease associated with periods of flares. Identifying patients at risk of severe disease and associated resource…
Abstract Number: 2076 • ACR Convergence 2022
Unfavorable Outcomes Associated with Current Standard of Care in the Management of Patients with Systemic Lupus Erythematosus
Zahi Touma¹, Sheena Kayaniyil², Anna Parackal², Dennisse Bonilla¹, Jiandong Su¹, Christina Qian³, Sally Miller³, Shelagh Szabo³ and Shelly Chandran², ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²AstraZeneca, Mississauga, ON, Canada, ³Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada
Background/Purpose: The effectiveness of current standard of care treatment including corticosteroids (CS) in Systemic Lupus Erythematosus (SLE) is limited and has potential side-effects. Given the…
Abstract Number: 0469 • ACR Convergence 2022
Factors Associated with Corticosteroid Dosing in the Management of Giant Cell Arteritis
Loukas Kakoullis and Shiv Sehra, Mount Auburn Hospital, Cambridge, MA
Background/Purpose: Corticosteroids are the cornerstone of therapy in patients with giant cell arteritis (GCA). Tapering regiments vary considerably in both dose and duration, while relapses…

« Previous Page
1
…
3
4
5
6
7
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].